| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 03/04/2003 | US6528542 Adjustment concentration |
| 03/04/2003 | US6528512 Cytokine specific binding protein; |
| 03/04/2003 | US6528509 Pyrazole compositions useful as inhibitors of ERK |
| 03/04/2003 | US6528508 A bicyclic nitrogen containing heteroaromatic compound useful for inhibiting protein kinase p38 which involved in cell proliferation, cell death and response to extracellular stimuli |
| 03/04/2003 | US6528263 Identifying a cell expressing protooncogene polypeptide by contacting a nucleic acid with a polynucleotide reagent and detecting its binding; can be used in diagnosis and treatment of cancer |
| 03/04/2003 | US6528096 Carrier mixed with additives having lubricant properties for preparing powdery pharmaceutical compositions for inhalation |
| 03/04/2003 | US6528084 Composition and method |
| 03/03/2003 | WO2002020496A1 2-guanidino-4-aryl-quinazoline |
| 03/03/2003 | WO2002019971A1 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds |
| 03/03/2003 | CA2421222A1 2-guanidino-4-aryl-quinazoline |
| 02/27/2003 | WO2003016916A1 Identification and isolation of somatic stem cells and uses thereof |
| 02/27/2003 | WO2003016549A2 Nucleic-acid associated proteins |
| 02/27/2003 | WO2003016530A1 Novel protein and its dna |
| 02/27/2003 | WO2003016351A2 N - cam related compounds modulating cell groth |
| 02/27/2003 | WO2003016299A1 Quinazolinone derivative |
| 02/27/2003 | WO2003016279A1 Fused-polycyclic compounds |
| 02/27/2003 | WO2003016273A2 Peptide arginals and methods for treating disseminated intravascular coagulation |
| 02/27/2003 | WO2003016270A2 Selective estrogen receptor modulators |
| 02/27/2003 | WO2003016269A1 5-amidino-n-(2-aminophenethyl)-n-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor |
| 02/27/2003 | WO2003015820A1 GnRH AGONIST COMBINATION DRUGS |
| 02/27/2003 | WO2003015819A1 Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b |
| 02/27/2003 | WO2003015810A1 Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof |
| 02/27/2003 | WO2003015805A1 Composition for removal of toxins |
| 02/27/2003 | WO2003015799A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/27/2003 | WO2003015797A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine |
| 02/27/2003 | WO2003015792A1 Anti-tumour 2-alkoxyestradiol sulfamates |
| 02/27/2003 | WO2003015791A1 Phophylactic and therapeutic use of hydroxysteroids |
| 02/27/2003 | WO2003015772A1 Inhibitors of polyq-aggregation |
| 02/27/2003 | WO2003015761A1 Selective estrogen receptor modulators |
| 02/27/2003 | WO2003015705A2 In situ immunization |
| 02/27/2003 | WO2003015704A2 Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders |
| 02/27/2003 | WO2003015516A1 Compositions and methods for treatment of mitochondrial diseases |
| 02/27/2003 | WO2003015494A2 Tocopherol enriched compositions and amelioration of inflammatory symptoms |
| 02/27/2003 | WO2003000181A3 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 02/27/2003 | WO2002092588A3 Aromatic sulfone hydroxamates and their use as protease inhibitors |
| 02/27/2003 | WO2002092129A3 Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist |
| 02/27/2003 | WO2002089740A3 Sulfonamides |
| 02/27/2003 | WO2002083135A3 Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence |
| 02/27/2003 | WO2002064590A3 Carboline derivatives |
| 02/27/2003 | WO2002062321A3 Method for producing a floating tablet containing an active principle |
| 02/27/2003 | WO2002060411A3 Process for production of nanoparticles and microparticles by spray freezing into liquid |
| 02/27/2003 | WO2002042436A3 Isolated human phosphatase proteins, nucleic acid molecules encoding them, and uses thereof |
| 02/27/2003 | WO2002028865A3 Condensed pyridoindole derivatives |
| 02/27/2003 | WO2002022212A3 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 02/27/2003 | WO2002022111A3 Combination of lipoic acids and conjugated acids for treating diabetic disorders |
| 02/27/2003 | WO2002000691A3 Polynucleotides and polypeptides encoded thereby |
| 02/27/2003 | WO2001098481A3 Renal regulatory elements and methods of use thereof |
| 02/27/2003 | WO2001092892A3 Methods to identify compounds that modulate rage |
| 02/27/2003 | US20030040536 For therapy of disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease |
| 02/27/2003 | US20030040533 For use as hypoglycaemic and hypolipidaemic agents |
| 02/27/2003 | US20030040523 Pyrimidine compounds and their use as modulators of chemokine receptor activity |
| 02/27/2003 | US20030040513 P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
| 02/27/2003 | US20030040509 Methods and compositions for treating diseases associated with excesses in ACE |
| 02/27/2003 | US20030040464 Method of treating or preventing attention defecit hyperactivity disorder |
| 02/27/2003 | US20030040007 Human BMP-7 promoter and method for exploring bone-related substance by using the same |
| 02/27/2003 | US20030039983 Nucleotide sequences coding polypeptide for use in the treatment, prevention and diagnosis of cancer |
| 02/27/2003 | US20030039654 Amino acid sequence of parathyroid hormone/parathyroid hormone related protein modulating domains and a vehicle for to stimulate renal calcium reabsorption |
| 02/27/2003 | US20030039627 Administering to the patient a therapeutically effective amount of an amine containing polymer |
| 02/27/2003 | US20030039626 Fat-binding polymers |
| 02/27/2003 | CA2458643A1 Nucleic-acid associated proteins |
| 02/27/2003 | CA2457632A1 Identification and isolation of somatic stem cells and uses thereof |
| 02/27/2003 | CA2457482A1 5-amidino-n-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor |
| 02/27/2003 | CA2457461A1 Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b |
| 02/27/2003 | CA2457453A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine |
| 02/27/2003 | CA2457452A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/27/2003 | CA2457436A1 Peptide arginals and methods for treating disseminated intravascular coagulation |
| 02/27/2003 | CA2457164A1 Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival of cells |
| 02/27/2003 | CA2457143A1 In situ immunization |
| 02/27/2003 | CA2457142A1 Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders |
| 02/27/2003 | CA2457043A1 Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof |
| 02/27/2003 | CA2456868A1 Inhibitors of polyq-aggregation |
| 02/27/2003 | CA2456743A1 Tocopherol enriched compositions and amelioration of inflammatory symptoms |
| 02/27/2003 | CA2456150A1 Selective estrogen receptor modulators |
| 02/26/2003 | WO2002020467A1 Novel crystals of n-hydroxy-2(s)-methyl-5-ethoxymethoxy -4(s)-[n-(4-phenoxyphenylcarbonyl)amino]pentanamide, process for their production and medicines containing the crystals as the active ingredient |
| 02/26/2003 | WO2002018407A2 Antisense oligonucleotides against vanilloid receptor 1 |
| 02/26/2003 | EP1285665A1 Liquid gonadotropin containing formulations |
| 02/26/2003 | EP1285657A2 Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| 02/26/2003 | EP1285653A1 Use of alpha-1L agonists in the treatment of incontinence |
| 02/26/2003 | EP1285087A2 Enzymatic assays for screening anti-cancer agents |
| 02/26/2003 | EP1285071A2 Novel dual oxidases as mitogenic and endocrine regulators |
| 02/26/2003 | EP1285063A1 Anti-angiogenic polypeptides |
| 02/26/2003 | EP1284974A2 Triazolyl tropane derivatives as ccr5 modulators |
| 02/26/2003 | EP1284963A1 Novel calcium receptor active molecules and method for preparing same |
| 02/26/2003 | EP1284959A1 Compounds for modulating the rage receptor |
| 02/26/2003 | EP1284956A1 Il-8 receptor antagonists |
| 02/26/2003 | EP1284727A1 Intracorporeal medicaments for photodynamic treatment of disease |
| 02/26/2003 | EP1284724A1 Method of preparing alkylated salicylamides via a dicarboxylate intermediate |
| 02/26/2003 | EP1284719A2 The use of a calcium channel blocker for treating renal disorders |
| 02/26/2003 | EP1284717A1 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base |
| 02/26/2003 | EP1042297B1 Carboxyl acid substituted heterocycles as metalloproteinase inhibitors |
| 02/26/2003 | EP0929571B1 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators |
| 02/26/2003 | EP0850059B1 Pharmaceutical formulations containing darifenacin |
| 02/26/2003 | EP0770137B1 Improvements in production of proteins in host cells |
| 02/26/2003 | EP0754040B1 Rapamycin derivatives |
| 02/26/2003 | CN1399678A Human Enzymes of metalloprotease family |
| 02/26/2003 | CN1399644A Novel human G-Protein coupled receptor |
| 02/26/2003 | CN1399638A Indoloazepines as vasopressin receptor antagonists |
| 02/26/2003 | CN1399636A Adenosine receptor antagonists and methods of making and using the same |
| 02/26/2003 | CN1399633A 嘧啶衍生物 Pyrimidine derivatives |
| 02/26/2003 | CN1399631A Novel hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines |